Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01032148
Other study ID # RPCI I 147408
Secondary ID
Status Terminated
Phase Phase 1
First received December 14, 2009
Last updated January 11, 2017
Start date December 2009
Est. completion date January 2017

Study information

Verified date January 2017
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participants' physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while on-study will help the researchers decide if LBH589 is safe and effective.


Description:

This is an open-label, standard 3-3 dose finding scheme with a modification that allows intra-patient dose modification to determine maximum tolerated dose and toxicity profile of LBH589 in patients with recurrent or refractory Hodgkin's or non-Hodgkin's lymphoma.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patients age = 18 years old with relapsed/refractory Hodgkin lymphoma or NHL patients who have relapsed or are refractory after receiving a minimum of two prior therapies

- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

Laboratory requirements:

- ANC = 1.5 x 10(9th)/L, unless due to bone marrow involvement with lymphoma

- Hemoglobin = 9 g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma

- Platelets = 100 x 10(9th)/L, unless due to bone marrow involvement with lymphoma

- Serum creatinine = 1.5 x Upper limit of Normal, or calculated Creatinine Clearance = 50 mL/min

- AST and ALT = 2.5 x Upper limit of Normal, unless due to liver involvement with lymphoma

- Serum bilirubin = 1.5 x Upper limit of Normal

- Albumin > 3.0 g/dl

- Serum potassium = Lower limit of Normal

- Total serum calcium [corrected for serum albumin] or ionized calcium = Lower limits of normal

- Serum magnesium = Lower limit of Normal

- Serum phosphorus = Lower limit of Normal

- TSH = LLN and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.

- Baseline MUGA or ECHO must demonstrate LVEF = 50%

- ECOG Performance Status of = 2

Exclusion Criteria:

- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

- Patients who will need valproic acid for any medication during the study or within 5 days prior to first LBH589 treatment

- Peripheral neuropathy = CTCAE grade 1

- Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

- Patients with congenital QT syndrome

- History or presence of sustained ventricular tachyarrhythmia.

- Any history of ventricular fibrillation or torsade de pointes

- Bradycardia defined as Heart Rate < 50 bpm. Patients with pacemakers are eligible if Heart Rate = 50 bpm

- Screening EKG with a QTc.450msec

- Right Bundle branch block + left anterior hemiblock (bifascicular block)

- Patients with myocardial infarction or unstable angina = 6 months prior to starting study drug

- other clinically significant heart disease (e.g. CHF NY Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen)

- Impairment of GI function or GI disease that may significantly alter the absorption of LBH589

- Patients with Diarrhea > CTCAE grade 1

- Other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values that could cause unaccepted safety risks or compromise compliance with the protocol

- Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug

- Concomitant use of CYP3A4 inhibitors

- Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites(which ever is longer) and who have not recovered from side effects of those therapies

- Patients who have received either immunotherapy within = 8 weeks;chemotherapy within = 4 weeks or radiation therapy to >30% of marrow-bearing bone within = weeks prior to starting study treatment or who have not yet recovered from side effects of such therapies

- Patients with an active bleeding tendency or is receiving any treatment with therapeutic doses of sodium warfarin or coumadin derivatives. Low doses of Coumadin (e.g.=2 mg/day) to maintain line patency is allowed.

- Patients who have undergone major surgery = 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

- Women who are pregnant or breast feeding or women of childbearing potential not using effective method of birth control

- Male patients whose sexual partners are women of childbearing potential not using effective birth control

- Patients with prior malignancy within 5 years (except for basal or squamous cell carcinoma, in situ cancer of the cervix or early stage prostate or bladder carcinomas)

- Patients with known positivity for HIV or hepatitis C: baseline testing for HIV and Hepatitis C is not required

- Prior allogenic stem cell transplant

- Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff

- Patients taking CYP2D6 inhibitors should be carefully monitored, but these drugs are not necessarily contraindicated when use concomitantly with LBH. Use of these drugs is not an exclusion criterion

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
LBH589
LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (2)

Lead Sponsor Collaborator
Roswell Park Cancer Institute Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine maximum tolerated dose (MTD) of LBH589 2 years Yes
Secondary Determine toxicity profile in study population 28 days after Cycle 2 Day 1 Yes
Secondary Determine anti-lymphoma activity of LBH589 in (non-CTCL) Hodgkin's and non-Hodgkin's lymphoma patients 2 Years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Completed NCT04152148 - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients Phase 1
Recruiting NCT05191225 - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study Phase 4
Recruiting NCT05096234 - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma Phase 2
Recruiting NCT05623982 - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Terminated NCT01699581 - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant Phase 2
Completed NCT01763398 - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study N/A
Completed NCT01205503 - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00969462 - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Phase 4
Completed NCT00659425 - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma Phase 1
Withdrawn NCT00577161 - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL Phase 3
Completed NCT00533728 - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma Phase 1
Completed NCT00608907 - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) Phase 1
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Completed NCT00430352 - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Phase 4
Completed NCT00581646 - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance N/A